Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Capital Expenditures (2016 - 2024)

Moleculin Biotech (MBRX) has 9 years of Capital Expenditures data on record, last reported at $13000.0 in Q2 2024.

  • For Q2 2024, Capital Expenditures fell 13.33% year-over-year to $13000.0; the TTM value through Mar 2025 reached $13000.0, down 50.0%, while the annual FY2024 figure was $13000.0, 50.0% down from the prior year.
  • Capital Expenditures reached $13000.0 in Q2 2024 per MBRX's latest filing, up from -$17000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $295000.0 in Q3 2020 and bottomed at -$67000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $36166.7, with a median of $17000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 3587.5% in 2020, then plummeted 452.63% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $60000.0 in 2020, then tumbled by 68.33% to $19000.0 in 2021, then tumbled by 452.63% to -$67000.0 in 2022, then soared by 74.63% to -$17000.0 in 2023, then surged by 176.47% to $13000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $13000.0 in Q2 2024, -$17000.0 in Q4 2023, and $28000.0 in Q3 2023.